Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24496349 | 0.82 | MAOB (0.58) | MAOBKMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL6035071 | 0.79 | TSHR (0.59) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL2673282 | 0.79 | TSHR (0.67) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL31350806 | 0.78 | CYP3A4 (0.79) | MAOBKMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL17938746 | 0.76 | ALDH1A1 (0.70) | MAOBKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL31350986 | 0.76 | MAOB (1.00) | MAOBKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL3153541 | 0.76 | TSHR (0.58) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL1771402 | 0.75 | KMT2A (0.59) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL4280546 | 0.74 | KMT2A (0.72) | MAOBKMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL27545187 | 0.74 | KMT2A (0.74) | MAOBKMT2AMEN1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145547-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM Fondazione Istituto Firc di Oncologia Molecolare (IT) | 2017-03-29 | — | — | EP | claimed |
| US-20170027896-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2017-02-02 | — | — | US | claimed |
| WO-2015155335-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2015-10-15 | — | — | WO | claimed |
| US-20100292170-A1 | METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN | UNIVERSITY OF ROCHESTER (US) | 2010-11-18 | — | — | US | claimed |
| WO-2009061847-A2 | METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN | UNIVERSITY OF ROCHESTER (US) | 2009-05-14 | — | — | WO | claimed |
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | PHARMACIA ITALIA S.P.A. (IT) | 2004-10-14 | — | — | US | claimed |
| EP-1406889-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | claimed |
| WO-2003006447-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | PHARMACIA ITALIA SPA (IT) | 2003-01-23 | — | — | WO | claimed |
| EP-3145547-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM Fondazione Istituto Firc di Oncologia Molecolare (IT) | 2017-03-29 | — | — | EP | disclosed |
| US-20170027896-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2017-02-02 | — | — | US | disclosed |
| WO-2015155335-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2015-10-15 | — | — | WO | disclosed |
| US-8415108-B2 | Methods for diagnosing interstitial cystitis via nuclear localization of beta-catenin | UNIVERSITY OF ROCHESTER (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100292170-A1 | METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN | UNIVERSITY OF ROCHESTER (US) | 2010-11-18 | — | — | US | disclosed |
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | PHARMACIA ITALIA S.P.A. (IT) | 2004-10-14 | — | — | US | disclosed |
| EP-1406889-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003006447-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | PHARMACIA ITALIA SPA (IT) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | TCF4, TCF7, TCF7L2 | MAOB 3240/4885KMT2A 3181/4885MEN1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.